MAPK14 and esophageal squamous cell carcinoma: Based on the possible results analyzed by AMDock software, we found that both of these two drugs showed excellent binding ability with MAPK14 (Figures 6D, E), suggesting that they may serve as anti-ESCC drugs through targeting MAPK14.